Skip to main content
BEAM $20.90 -0.19%
BEAM logo
BEAM · Beam Therapeutics Inc.
Track BEAM — free
$20.90 -0.04 (-0.19%) At close · Nov 20 Play latest call Q4 2025 earnings call transcript
Market Cap
$2.16B
Shares
103.50M
Volume · Nov 20 3.89M Avg daily vol (3M) 2.05M
All webcasts

Earnings call · FY2026 Q3

Beam Therapeutics Inc. (BEAM) Q3 2026 Earnings Call

Concluded Oct 27, 2026
Oct 27, 2026
Period
FY2026 Q3
Runtime
—
Sources
2 artifacts
Revenue $307,000 -96.8% YoY
Diluted EPS -$1.28
Net income -$134.41M
Open full screen 8-K 10-Q

Executive readout · one minute

What the filings say

8-K earnings release · filed Nov 3, 2026
Beam Therapeutics expects to submit risto-cel's BLA as early as year-end 2026. It ended the third quarter with $1.0 billion in cash, cash equivalents and marketable securities, with runway expected into mid-2029.
10-Q report · filed Nov 3, 2026
Beam Therapeutics plans to submit a biologics license application (BLA) for risto-cel as early as year-end 2026, after completing dosing for all adult and adolescent patients in its BEACON trial.

The audio replay and transcript follow the call.

Research coverage

2 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

Full-screen source Call document